Lipocine (NASDAQ:LPCN) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN) in a research report sent to investors on Friday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Lipocine Stock Performance

Shares of Lipocine stock opened at $3.35 on Friday. The firm’s 50-day simple moving average is $3.95 and its 200-day simple moving average is $4.52. Lipocine has a twelve month low of $2.91 and a twelve month high of $11.79. The firm has a market cap of $17.92 million, a P/E ratio of -4.41 and a beta of 1.42.

Institutional Trading of Lipocine

A hedge fund recently raised its stake in Lipocine stock. Geode Capital Management LLC raised its position in Lipocine Inc. (NASDAQ:LPCN) by 6.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 57,464 shares of the specialty pharmaceutical company’s stock after buying an additional 3,248 shares during the period. Geode Capital Management LLC owned 1.07% of Lipocine worth $280,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.